Investigating Notch and related pathways for new biomarkers in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is the 5th commonest cause of cancer related death in the UK with a 5-year survival rate of only 4%. This is due to vague symptoms, late presentation and lack of availability of decent biomarkers, making most PDAC unsuitable for curative resections at the time...
Main Author: | Masood, Muhammad Mehdi |
---|---|
Other Authors: | Neal, Christopher ; Jones, Donald |
Published: |
University of Leicester
2017
|
Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.733685 |
Similar Items
-
The role of Notch3 and related pathways in pancreatic cancer
by: Doucas, Helena
Published: (2006) -
Notch3 and HEY-1 as prognostic biomarkers in pancreatic adenocarcinoma.
by: Christopher D Mann, et al.
Published: (2012-01-01) -
The Notch pathway as a biomarker in pancreatic ductal adenocarcinoma and its potential therapeutic modulation
by: Mann, Christopher David
Published: (2012) -
The Notch pathway is important in maintaining the cancer stem cell population in pancreatic cancer.
by: Ethan V Abel, et al.
Published: (2014-01-01) -
The MEK/ERK pathway promotes NOTCH signalling in pancreatic cancer cells.
by: Isabelle Tremblay, et al.
Published: (2013-01-01)